Publikationen (59) Publikationen von Ana Alfonso Piérola

filter_list

2025

  1. A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS

    British Journal of Haematology, Vol. 207, Núm. 2, pp. 624-630

  2. From Sanger to Oxford Nanopore MinION Technology: The Impact of Third-Generation Sequencing on Genetic Hematological Diagnosis

    Cancers, Vol. 17, Núm. 11

  3. Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignances

    Molecular Therapy Methods and Clinical Development, Vol. 33, Núm. 1

  4. Hematopoietic Stem Cell Hierarchies as Novel Biomarkers of Drug Response in Myelodysplastic Syndromes and Acute Myeloid Leukemia

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 31, Núm. 17, pp. 3618-3627

  5. Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome

    Leukemia Research, Vol. 156

  6. Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study

    Cancer, Vol. 131, Núm. 1

2024

  1. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  2. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

    Clinical and Translational Science, Vol. 17, Núm. 3

  3. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma

    Blood Advances, Vol. 8, Núm. 21, pp. 5479-5492

  4. Myelodysplastic neoplasms

    Medicina Clinica, Vol. 162, Núm. 2, pp. 77-82

  5. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

    Nature Communications, Vol. 15, Núm. 1

  6. Síndromes mielodisplásicos. Neoplasias mielodisplásicas/ mieloproliferativas

    Pregrado de Hematología (Asociación Española de Hematologia y Hemoterapia), pp. 545-566

  7. Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

    Blood Advances

2023

  1. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

    The Lancet Haematology, Vol. 10, Núm. 2, pp. e117-e128

  2. CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

    Hematology, Transfusion and Cell Therapy, Vol. 45, Núm. 2, pp. 266-274

  3. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  4. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

    Frontiers in Immunology, Vol. 14

  5. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

    Leukemia Research, Vol. 134

  6. Severe laryngeal edema after CAR-T cell treatment in a patient with multiple myeloma: a case report

    Clinical Case Reports, Vol. 11, Núm. 6, pp. e7281

  7. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution

    eLife, Vol. 12